Differences in the clinicopathological phenotypes of tauopathies (including Alzheimer disease) may relate to differences in the strain properties of toxic tau species.16 However, here we use a large clinicopathological cohort based on the latest MDS diagnostic criteria to show that the clinical phenotype of PSP relates in part to genetic variants that may determine regional susceptibility. The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.